158 related articles for article (PubMed ID: 31256738)
1. High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.
Meher-Homji Z; Tam CS; Siderov J; Seymour JF; Holmes NE; Chua KYL; Phillips EJ; Slavin MA; Trubiano JA
Leuk Lymphoma; 2019 Dec; 60(14):3455-3460. PubMed ID: 31256738
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
3. [Hypersensitivity reactions to multiple drugs during the course of hairy cell leukemia treated with 2-chlorodeoxyadenosine].
Kokunai A; Azusawa H; Murota H; Ohhata C; Katayama I; Murata S; Tadokoro S
Arerugi; 2006 Jun; 55(6):662-6. PubMed ID: 16883103
[TBL] [Abstract][Full Text] [Related]
4. High incidence of skin rash in patients with hairy cell leukemia treated with cladribine.
Ganzel C; Gatt ME; Maly A; Ben-Yehuda D; Goldschmidt N
Leuk Lymphoma; 2012 Jun; 53(6):1169-73. PubMed ID: 22035415
[TBL] [Abstract][Full Text] [Related]
5. Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Tadmor T; Levy I; Herishanu Y; Goldschmidt N; Bairey O; Yuklea M; Shvidel L; Fineman R; Aviv A; Ruchlemer R; Braester A; Dally N; Rouvio O; Shaulov A; Greenbaum U; Inbar M; Polliack A
Leuk Res; 2019 Jul; 82():24-28. PubMed ID: 31152919
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic exposure is associated with cutaneous adverse events in hairy cell leukemia patients treated with purine analogues.
Wang RF; Li D; Kuehn GJ; Andritsos LA; Grever MR; Kaffenberger BH
J Am Acad Dermatol; 2019 Jun; 80(6):1762-1764. PubMed ID: 30205132
[No Abstract] [Full Text] [Related]
7. The burden of antibiotic allergies in adults in an Australian intensive care unit: the BASIS study.
Moran RL; Devchand M; Churilov L; Warrillow S; Trubiano JA
Crit Care Resusc; 2019 Dec; 21(4):265-73. PubMed ID: 31778633
[TBL] [Abstract][Full Text] [Related]
8. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.
Robak T; Jamroziak K; Gora-Tybor J; Blonski JZ; Kasznicki M; Dwilewicz-Trojaczek J; Wiater E; Zdunczyk A; Dybowicz J; Dmoszynska A; Wojtaszko M; Zdziarska B; Calbecka M; Kostyra A; Hellmann A; Lewandowski K; Stella-Holowiecka B; Sulek K; Gawronski K; Skotnicki AB; Nowak W; Zawilska K; Molendowicz-Portala L; Kloczko J; Sokolowski J; Warzocha K; Seferynska I; Ceglarek B; Konopka L
Blood; 2007 May; 109(9):3672-5. PubMed ID: 17209059
[TBL] [Abstract][Full Text] [Related]
9. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hairy cell leukemia-variant with cladribine.
Tetreault SA; Robbins BA; Saven A
Leuk Lymphoma; 1999 Oct; 35(3-4):347-54. PubMed ID: 10706459
[TBL] [Abstract][Full Text] [Related]
11. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
12. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
13. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
Hacioglu S; Bilen Y; Eser A; Sivgin S; Gurkan E; Yildirim R; Aydogdu I; Dogu MH; Yilmaz M; Kayikci O; Tombak A; Kuku I; Celebi H; Akay MO; Esen R; Korkmaz S; Keskin A
Hematol Oncol; 2015 Dec; 33(4):192-8. PubMed ID: 25393847
[TBL] [Abstract][Full Text] [Related]
14. Purine analog toxicity in patients with hairy cell leukemia.
Tadmor T
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():38-42. PubMed ID: 21463124
[TBL] [Abstract][Full Text] [Related]
15. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine.
Sigal DS; Sharpe R; Burian C; Saven A
Blood; 2010 Mar; 115(10):1893-6. PubMed ID: 20056789
[TBL] [Abstract][Full Text] [Related]
16. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
17. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.
Huynh E; Sigal D; Saven A
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():12-7. PubMed ID: 19814692
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol.
Chubar Y; Bennett M
Br J Haematol; 2003 Sep; 122(5):768-70. PubMed ID: 12930387
[TBL] [Abstract][Full Text] [Related]
19. Impact of antibiotic allergy labels on patient outcomes in a tertiary paediatric hospital.
Catalano AC; Pittet LF; Choo S; Segal A; Stephens D; Cranswick NE; Gwee A
Br J Clin Pharmacol; 2022 Mar; 88(3):1107-1114. PubMed ID: 34388858
[TBL] [Abstract][Full Text] [Related]
20. [Clinical analysis of 24 patients of hairy cell leukemia treated by cladribine].
Wang TY; Li ZJ; Lyu R; Fu MW; Sui WW; Huang WY; Liu W; An G; Deng SH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):491-495. PubMed ID: 30032567
[No Abstract] [Full Text] [Related]
[Next] [New Search]
